Another very strong week with spreads 9bps tighter on average. Absence of supply ahead of earnings season helped.
• Astra Zeneca was the top performer at 14bps tighter. The company is said to be considering relisting in the US. Separately, Bloomberg said that it is in talks with Summit Therapeutics to license a competitor drug to Merck’s Keytruda ($31bn annual sales). The deal is said to be worth up to $15bn but this would be contingent on milestone/performance payments. The upfront cost would be “several” billions.
• Bayer’s date with the Supreme Court may be closer and the SCOTUS is seeking the advice of the Solicitor General. Bayer talked up the development, but the equity market was less sanguine. Bonds -7bps tighter in line with the sector.
• Merck KgaA closed the $3.4bn Springworks acquisition. This will likely require issuance. CEO Belen Garijo told Bloomberg that “If we find something bigger, we’ll be able to do it as well.” Despite this, bonds were 9bps tighter.

Find more articles and bullets on these widgets:
From market source
The 10-Year gilt/Bund spread is back below 210bp, with gilts outperforming Bunds as Tsys rally in the wake of the ADP employment data and Trump’s latest critique of Fed Chair Powell.
Fig. 1: UK 10-Year Gilt Yield (%)

Source: MNI - Market News/Bloomberg
Some highlights from the S&P Global report on Canada Services PMI (link), which showed a broad improvement vs April (45.6 vs 41.5 prior):
